Ivan Cheung, Eisai US chairman and CEO

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

In the first look at Phase III da­ta for lecanemab, Ei­sai and Bio­gen’s fol­low-up Alzheimer’s drug to the em­bat­tled Aduhelm launch, re­sults show the drug passed with fly­ing col­ors on a test look­ing at mem­o­ry, prob­lem solv­ing and oth­er de­men­tia met­rics.

One of the most-watched Alzheimer’s ther­a­pies in the clin­ic, lecanemab met the study’s pri­ma­ry goal on the CDR-SB — Clin­i­cal De­men­tia Rat­ing-Sum of Box­es — giv­ing the biotech the con­fi­dence to ask for full ap­proval in the US, EU and Japan by next March 31. The ex­per­i­men­tal drug re­duced clin­i­cal de­cline on the scale by 27% com­pared to place­bo at 18 months, the com­pa­nies said Tues­day night East­ern time and Wednes­day morn­ing in Japan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.